← Back to Search

Procedure

Treatment for Movement Disorders (LAANTERN Trial)

N/A
Waitlist Available
Led By Eric Leuthardt, MD
Research Sponsored by Monteris Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2600 procedures conducted at over 70 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, QoL, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 1,000 patients and up to 50 sites.

Eligible Conditions
  • Epilepsy
  • Movement Disorders
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Quality of Life
Number of patients demonstrating local control, overall survival, and seizure freedom (ENGEL and ILAE classifications)
Reason for NeuroBlate
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Monteris MedicalLead Sponsor
9 Previous Clinical Trials
563 Total Patients Enrolled
Eric Leuthardt, MDPrincipal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
56 Total Patients Enrolled
~105 spots leftby Nov 2025